Rare Disease Clinical Trial Feasibility Tool
Rare Disease Management announced its rare disease clinical trial feasibility tool
Rare Disease Management (RDM)
, a clinical development company, based in Wilmington, NC focusing primarily on orphan and rare diseases, announced its rare disease clinical trial feasibility tool that enables pharmaceutical, biotech and CRO clients to best identify the top investigators in orphan and rare diseases. The tool— ExpertSense—was developed by RDM in collaboration with the Technical University of Denmark Bioinformatics team. That team was also responsible for the introduction of FindZebra, a investigator tool that helps give rare disease investigators a hypothesis for rare diseases.
Empowering Sites and Patients: The Impact of Personalized Support in Clinical Trials
November 26th 2024To meet the growing demands of clinical research, sponsors must prioritize comprehensive support models, such as clinical site ambassadors and patient journey coordinators, who can address operational challenges and improve site relationships, patient satisfaction, and overall trial efficiency.
Driving Diversity with the Integrated Research Model
October 16th 2024Ashley Moultrie, CCRP, senior director, DEI & community engagement, Javara discusses current trends and challenges with achieving greater diversity in clinical trials, how integrated research organizations are bringing care directly to patients, and more.
FDA Finalizes Decentralized Clinical Trial Guidance
November 25th 2024The FDA's guidance is part of a broader effort to modernize clinical trials, improve efficiency, reduce participant burden, and expand access, particularly for underrepresented populations and those in geographically or economically constrained areas.
AI in Clinical Trials: A Long, But Promising Road Ahead
May 29th 2024Stephen Pyke, chief clinical data and digital officer, Parexel, discusses how AI can be used in clinical trials to streamline operational processes, the importance of collaboration and data sharing in advancing the use of technology, and more.
